Marksans Pharma Limited announced on May 15 that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare Products Regulatory Agency (UKMHRA) for Gabapentin 50 mg/ml oral solution.
The regulatory approval marks a significant addition to the company’s neurology-focused portfolio in the UK market. Gabapentin is commonly prescribed for the treatment of nerve pain and epilepsy.
Marksans Pharma, headquartered in Mumbai, is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations. Its facilities in India, the US, and the UK are approved by major global regulatory bodies including the USFDA, UKMHRA, and TGA Australia. The company’s portfolio spans key therapeutic areas including cardiovascular, central nervous system (CNS), anti-diabetics, pain management, gastroenterology, and anti-allergy segments.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult your financial advisor before making any investment decisions.